I usually recommend a bx to confirm the presence of metastatic disease. I ensure that all other biomarker information is available, including PD-L1 is obtained, of not performed already. In the absence of actionable/ targetable mutations, I offer patients a KN189/KN407 type regimen at the time of pr...

In the new era of cancer IO therapy, it is real important to ascertain and determine how to define "progression" and what the "pattern of progression" is. Assuming genuine disease progression (in terms of pattern and burden of disease) while "on durvalumab" in stage III NSCLC, would biopsy whenever ...